Skip to content
The Nexus
DossierENTITY

Organon

Coverage of Organon in the Nexus archive.

Earliest in view: Apr 10 · 11:54 UTCMost recent: May 6 · 01:00 UTC
Co-mentioned in this coverage
Sun Pharmaorganization3Paul O'Driscollperson1Grünenthalorganization1Blood pressuretopic1CoreWeaveorganization1Docusignorganization1Lumentumorganization1S&P 500 Indextopic1CPI datatopic1
Recent coverage
  • BUSINESSMay 6 · 01:00 UTCBLOOMBERG
    Sun Pharma Explores Funding Mix for $12 Billion Organon Deal

    Sun Pharma is exploring funding options for its $12 billion deal to acquire Organon. The deal is a significant investment for Sun Pharma and requires careful consideration of funding sources. The company is weighing its options to secure the necessary funds.

  • BUSINESSApr 27 · 00:19 UTCBLOOMBERG
    Sun Pharma to Acquire US-Listed Organon in $12 Billion Deal

    Sun Pharma is set to acquire US-listed Organon in a $12 billion deal. The transaction marks a significant expansion for Sun Pharma in the pharmaceutical sector.

  • BUSINESSApr 16 · 05:46 UTCBLOOMBERG
    Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon

    Sun Pharma and Grünenthal are reportedly competing to acquire US-listed pharmaceutical company Organon. The news highlights potential strategic moves in the pharmaceutical sector.

  • BUSINESSApr 10 · 11:54 UTCBLOOMBERG
    US Premarket Movers: CoreWeave, Docusign, Lumentum, Organon

    The S&P 500 Index futures show minimal movement as of 7:50 a.m. in New York, with a seven-day winning streak potentially facing考验 due to upcoming CPI data. Key premarket movers include CoreWeave, Docusign, Lumentum, and Organon.